retatrutide trial weight loss Lilly's triple agonist achieves 16.8% in phase 3 The numbers from Lilly's Phase

Many details remain under investigation

It may interact with certain medications and isn't recommended during pregnancy or breastfeeding, as its effects aren't fully understood

The USA is expected to record an 18.1% CAGR from 2026 to 2036 due to employer purchasing and direct-to-consumer access

Endoplasmic reticulum protein quality control in neurodegenerative disease: the good, the bad and the therapy

This preference shift supports the theory that GLP-1 class medications fundamentally alter food reward processing in the brain, not just hunger signaling

Activation of these receptors may reduce the hedonic drive to eat, the pleasure-seeking component of appetite that makes you want to eat even when you are not physically hungry